Cadent Capital Advisors LLC Purchases 1,060 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Cadent Capital Advisors LLC lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,160 shares of the company’s stock after purchasing an additional 1,060 shares during the quarter. Cadent Capital Advisors LLC’s holdings in Hims & Hers Health were worth $1,745,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after buying an additional 2,152 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC lifted its stake in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Quarry LP grew its holdings in Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock valued at $113,000 after purchasing an additional 2,913 shares during the period. Finally, Amalgamated Bank increased its position in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after buying an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HIMS shares. Canaccord Genuity Group increased their price target on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, December 2nd. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Citigroup lowered shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their price objective for the company from $24.00 to $25.00 in a research note on Friday. Finally, Needham & Company LLC increased their target price on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $25.13.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now directly owns 67,015 shares in the company, valued at approximately $1,399,273.20. This trade represents a 73.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total transaction of $47,738.99. Following the transaction, the insider now owns 172,274 shares of the company’s stock, valued at $3,516,112.34. This represents a 1.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,063,707 shares of company stock valued at $28,696,798 in the last three months. 17.71% of the stock is owned by insiders.

Hims & Hers Health Price Performance

Shares of HIMS stock traded up $0.09 during mid-day trading on Monday, hitting $25.50. 6,863,560 shares of the stock traded hands, compared to its average volume of 9,132,327. The stock’s fifty day moving average is $27.21 and its two-hundred day moving average is $21.64. Hims & Hers Health, Inc. has a 52-week low of $8.14 and a 52-week high of $35.02. The stock has a market cap of $5.57 billion, a P/E ratio of 57.96 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the business posted ($0.04) EPS. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.